Skip to main content

What is the difference between Cabometyx and Cometriq?

Medically reviewed by N. France, BPharm. Last updated on Sep 24, 2021.

Official Answer

by Drugs.com

Cabometyx and Cometriq are two brand name drugs that both contain the same active ingredient cabozantinib, a kinase inhibitor used to treat certain types of cancer. Cabozantinib inhibits multiple tyrosine kinases, including the MET, AXL and VEGF receptors.

Cabometyx and Cometriq are taken once per day and are both marketed by Exelixis in the US.

The two drugs are not bioequivalent however. That is to say, you can’t switch between the two brands.

Cabometyx and Cometriq come in different oral formulations and are used to treat different types of cancer

Cabometyx Cometriq
Marketed since 2016 2012
Dosage form Tablets Capsules
Strength 20, 40 and 60 mg 20 and 80 mg
Used to treat
  • Advanced renal cell carcinoma (RCC)
  • Advanced RCC as a first-line treatment in combination with nivolumab
  • Hepatocellular carcinoma (HCC) in patients who have previously been treated with sorafenib
  • Locally advanced or metastatic differentiated thyroid cancer that has progressed following VEGFR-targeted therapy in people who do not respond to or are unable to take radioactive iodine
  • Progressive metastatic medullary thyroid cancer (MTC)
References

Related Medical Questions

Drug Information

Related Support Groups